Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

Mark A Ainsworth, Klaus Bendtzen, Jørn Brynskov

    Research output: Contribution to journalJournal articleResearchpeer-review

    158 Citations (Scopus)

    Abstract

    To investigate if the combined assessment of anti-infliximab antibodies (Ab) and the degree of TNF-alpha binding capacity (TNF-alpha-BC) afforded by infliximab may predict the response to infliximab treatment in patients with Crohn's disease (CD).
    Original languageEnglish
    JournalAmerican Journal of Gastroenterology
    Volume103
    Issue number4
    Pages (from-to)944-8
    Number of pages5
    ISSN0002-9270
    DOIs
    Publication statusPublished - 2007

    Bibliographical note

    Keywords: Adult; Antibodies, Monoclonal; Crohn Disease; Female; Humans; Male; Middle Aged; Predictive Value of Tests; Radioimmunoassay; Retrospective Studies; Statistics, Nonparametric; Treatment Outcome; Tumor Necrosis Factor-alpha

    Cite this